Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG -1.71%60 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus rates TXG with a GF Score™ of 60/100 and a GF Value™ of $18.91 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 280 Healthcare Providers & Services companies, 10x Genomics ranks worse than 357142.5% on this metric.
10x Genomics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for 10x Genomics's 5-Year Yield-on-Cost % or its related term are showing as below:
TXG's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.93 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
10x Genomics 5-Year Yield-on-Cost % Related Terms
TXG vs DOCS, WAY, PRVA: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, 10x Genomics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of 10x Genomics is calculated as
10x Genomics (TXG) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #999999 out of 280 companies in the Healthcare Providers & Services industry.
Is 10x Genomics' 5-Year Yield-on-Cost % too high?
10x Genomics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, 10x Genomics ranks #999999 out of 280 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' 5-Year Yield-on-Cost % compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #999999 out of 280 companies for 5-Year Yield-on-Cost %. This places 10x Genomics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 280 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.91, compared to a current price of $43.74 — trading 131.3% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. 10x Genomics' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For 10x Genomics (TXG), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $43.74 is trading 131.3% above its estimated GF Value™ of $18.91.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
5-Year Yield-on-Cost %: 0.00
GF Value™: $18.91 vs. price of $43.74 (131.3% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
60GF Score
Get the complete analysis for TXG
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
